论文部分内容阅读
次级淋巴趋化因子 (SLC)是体内重要的CC趋化因子成员 ,被认为是第一个参与体内淋巴细胞归巢的趋化因子 ,其组织分布主要是外周淋巴组织或器官 ,趋化体内多种淋巴细胞 (包括T细胞、B细胞、NK细胞、树突状细胞 )到外周淋巴组织或器官 ,这一粘附过程的主要涉及二种整合素α1β2 (LFA)和α4 β7,它们的配体分别时表达于HEV表面的ICAM 1或ICAM 2和MAdCAM ,另外α淋巴毒素和核因子κΒ诱导激酶也可通过SLC影响淋巴细胞归巢。基于其对多种效应细胞的趋化和调节作用 ,目前开展了许多应用研究工作。无论是重组蛋白注射还是基因修饰瘤苗均显示极强的抗肿瘤作用 ,在肿瘤局部和全身检测到系统性和局部免疫反应 ,包括CD4 +T细胞、CD8+T细胞和树突状细胞浸润 ,并伴有Th1类细胞因子上调 ;动物实验显示SLC可以通过树突状细胞调节先天性或 /和获得性免疫 ,参与抗急性炎症作用 ;在抗接触性超敏反应研究中 ,SLC抗体可以抑制郎格罕氏细胞迁移到淋巴结 ,这一研究提示一个新的治疗和预防皮肤变态反应性疾病的思路 ,即通过注射抗体或趋化因子阻断剂来干预抗原递呈细胞的功能从而抑制效应T细胞的致敏、活化
Secondary lymphotactin (SLC) is an important member of the CC chemokines in vivo and is believed to be the first chemokine involved in lymphocyte homing in vivo. Its tissue distribution is mainly peripheral lymphoid tissues or organs, chemotactic body A variety of lymphocytes (including T cells, B cells, NK cells, dendritic cells) to the peripheral lymphoid tissues or organs, this adhesion process mainly involves two integrins α1β2 (LFA) and α4 β7, their distribution When expressed separately on the surface of HEV ICAM 1 or ICAM 2 and MAdCAM, in addition α-lymphotoxin and nuclear factor κB-induced kinase can also affect lymphocyte homing through SLC. Based on its chemotactic and regulatory effects on a variety of effector cells, many applied research efforts are currently under way. Both recombinant protein injections and genetically modified vaccine show strong antitumor effects, both systemic and local immune responses including CD4 + T cells, CD8 + T cells and dendritic cells infiltration were detected locally and systemically, And associated with Th1-type cytokines upregulation; animal experiments show that SLC can regulate innate and / or acquired immunity through dendritic cells and participate in the anti-acute inflammation; in the study of anti-contact hypersensitivity, SLC antibody can inhibit Lang This finding suggests a new way of treating and preventing skin allergic diseases by interfering with the function of antigen-presenting cells by injection of antibodies or chemokine blockers, thereby inhibiting effector T cells Sensitization, activation